日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. TPBG (PF-06263507 Biosimilar) Recombinant Monoclonal Antibody

TPBG (PF-06263507 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA024093MB2HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    TPBG（PF-06263507 Biosimilar Antibody）重組單克隆抗體，其靶點(diǎn)為滋養(yǎng)層糖蛋白（TPBG），該蛋白也被稱為5T4癌胚抗原、5T4癌胚滋養(yǎng)層糖蛋白、5T4癌滋養(yǎng)層糖蛋白、M6P1、Wnt激活抑制因子1（WAIF1）等，在多種腫瘤中高表達(dá)，是重要的腫瘤相關(guān)抗原。本抗體以重組人TPBG蛋白制備，具有高度的種屬反應(yīng)性，主要針對人類TPBG蛋白發(fā)揮特異性結(jié)合作用。 靶向TPBG類似物因5T4在胚胎發(fā)育過程中短暫表達(dá)，而在成人正常組織中低表達(dá)或不表達(dá)，但在肺癌、乳腺癌、結(jié)直腸癌、卵巢癌等多種惡性腫瘤中異常高表達(dá)，與腫瘤的侵襲、轉(zhuǎn)移及不良預(yù)后密切相關(guān)，作為腫瘤治療的潛在靶點(diǎn)備受關(guān)注。此類藥物通過特異性結(jié)合腫瘤細(xì)胞表面的5T4抗原，可能通過抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用（ADCC）、補(bǔ)體依賴的細(xì)胞毒性作用（CDC）等機(jī)制殺傷腫瘤細(xì)胞，或作為載體偶聯(lián)細(xì)胞毒素、放射性同位素等形成抗體偶聯(lián)藥物（ADC），實(shí)現(xiàn)對腫瘤的精準(zhǔn)靶向治療。目前，相關(guān)臨床研究主要集中在評估其治療多種實(shí)體瘤的安全性、耐受性及抗腫瘤活性，探索其在聯(lián)合化療、免疫治療等方案中的協(xié)同效應(yīng)，為晚期或轉(zhuǎn)移性腫瘤患者提供新的治療選擇。 在TPBG重組單克隆抗體是研究TPBG蛋白功能及腫瘤發(fā)生發(fā)展機(jī)制的重要工具。研究者可利用該抗體進(jìn)行實(shí)驗(yàn)，檢測細(xì)胞或組織中TPBG蛋白的表達(dá)水平、亞細(xì)胞定位及相互作用蛋白，深入探究其在腫瘤細(xì)胞增殖、凋亡、上皮-間質(zhì)轉(zhuǎn)化（EMT）、血管生成等生物學(xué)過程中的作用機(jī)制。此外，通過構(gòu)建TPBG高表達(dá)或敲除的細(xì)胞模型及動(dòng)物模型，結(jié)合該抗體進(jìn)行功能驗(yàn)證，有助于揭示TPBG作為腫瘤標(biāo)志物的潛在價(jià)值及作為治療靶點(diǎn)的可行性，為腫瘤的早期診斷和新型靶向藥物的研發(fā)提供實(shí)驗(yàn)依據(jù)。同時(shí)，該抗體的種屬反應(yīng)性為人類，確保了在人體細(xì)胞及組織樣本研究中的特異性和準(zhǔn)確性，推動(dòng)了從基礎(chǔ)研究到臨床轉(zhuǎn)化的相關(guān)探索。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Trophoblast glycoprotein antibody; 5T4 oncofetal antigen antibody; 5T4 oncofetal trophoblast glycoprotein；5T4 oncotrophoblast glycoprotein antibody; M6P1 antibody; Wnt-activated inhibitory factor 1；WAIF1 antibody; TPBG antibody; 5T4
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human TPBG protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 功能：
    May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.
  • 基因功能參考文獻(xiàn)：
    1. In extravillous trophoblasts, 5T4 may function in epithelial-to-mesenchymal transition during placentation. The role of syncytiotrophoblast 5T4 is unknown, but its abundance in shed syncytial vesicles may signify route of sensitization of the maternal immune system. PMID: 28481180
    2. Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of cancer stem cells (CSC), and prevents local recurrence and suggest a novel therapeutic approach for patients with head and neck squamous cell carcinoma. PMID: 27780858
    3. We obtained GWS evidence (P < 2.7 x 10(-6)) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 x 10(-6)). PMID: 28183528
    4. In conclusion, the present study provided evidence that TPBG is involved in PDAC metastasis, and that TPBG and its associated signaling pathways may be a suitable target for pancreatic ductal adenocarcinoma therapy. PMID: 25738465
    5. 5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling PMID: 25066861
    6. Tyrosine 325 plus the leucine-rich repeat 1 surface centered on a second exposed aromatic residue, phenylalanine 97, are essential for inhibition of Wnt/beta-catenin signaling. PMID: 24582434
    7. The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure. PMID: 22956548
    8. 5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognised by 5T4-specific cytotoxic T-cells. PMID: 22498111
    9. Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen PMID: 11903056
    10. Results sugest that 5T4 is a transient marker of human embryonic stem cell differentiation & that 5T4 phenotype, colony seeding density and culture conditions influence the maintenance of pluripotent hES cells and their differentiation to neural lineages. PMID: 16616918
    11. there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified PMID: 16646078
    12. the mRNA expression of trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia. PMID: 17978129
    13. 5T4-based cancer vaccine: cytotoxic T lymphocyte epitopes identified in Trovax-vaccinated colorectal cancer patients PMID: 18567615
    14. colorectal cancer patients who had preexisting cell proliferative responses to 5T4 were longer-term survivors PMID: 18833005

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed by all types of trophoblasts as early as 9 weeks of development. Specific for trophoblastic cells except for amniotic epithelium. In adult tissues, the expression is limited to a few epithelial cell types but is found on a variety of carcinoma.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 12004

    OMIM: 190920

    KEGG: hsa:7162

    STRING: 9606.ENSP00000358765

    UniGene: Hs.71947



×
生命科學(xué)計(jì)算平臺(tái)